Human Fibrinogen Concentrate in Pediatric Cardiac Surgery
Status:
Completed
Trial end date:
2020-12-24
Target enrollment:
Participant gender:
Summary
The goal of the study is to determine whether the use of Human Fibrinogen Concentrate
(RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and
infants undergoing cardiopulmonary bypass.